![]() | ![]() |
Formats:
|
||||
Effect of new beta-adrenergic blocking agent, Atenolol (Tenormin), on pain frequency, trinitrin consumption, and exercise ability. This article has been cited by other articles in PMC.Abstract In 11 patients with severe angina pectoris a new beta-blocking drug, atenolol (Tenormin; I.C.I.66082), was found in a double-blind randomized trial to reduce significantly the frequency of anginal attacks (P less than 0-001) and the amount of trinitrin consumed (P less than 0-03) in comparison with practolol and placebo. There was no significant improvement in the patients' ability to exercise on the bicycle ergometer. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (573K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. Selected References These references are in PubMed. This may not be the complete list of references from this article.
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||